Clinical Trial Update: The Eplontersen Pregnancy and Lactation Outcomes Study

View source ↗

Summary

The Eplontersen pregnancy and lactation outcomes study (NCT07205666) sponsored by AstraZeneca is currently recruiting for transthyretin amyloidosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloidosis

Drugs mentioned

• Eplontersen (eplontersen)

Snippet

Sponsor: AstraZeneca | Conditions: Transthyretin Amyloidosis | Status: RECRUITING